Increased responsiveness and decreased expression of G proteins in deoxycorticosterone hypertension.
Deoxycorticosterone-salt (DOCA-salt) hypertension is characterized by elevated vasoconstriction to agonists that stimulate G protein-mediated activation of phospholipase C. However, the mechanisms responsible for the augmented responsiveness are unknown. This study tested the hypothesis that this augmented vascular responsiveness is due to elevated content of G(alpha)q, the G protein alpha-subunit that activates phospholipase C. Thoracic aortae from DOCA-salt hypertensive rats (systolic blood pressure 183 +/- 7 mm Hg) and normotensive controls (systolic blood pressure 115 +/- 2 mm Hg) were homogenized and G protein content determined. Western analysis revealed that G(alpha)i content was decreased in DOCA compared with control rats (1364 +/- 196 versus 2343 +/- 188 densitometry units, P < or = .05) with no differences observed for G(alpha)q or G(alpha)s. In addition, contractile responses in denuded femoral artery strips revealed a significant decrease in EC50 values in DOCA arteries to all of the agonists examined: aluminum fluoride (DOCA = 1.42, control = 2.34 mmol/L), mastoparan (DOCA = 0.51, control = 35 micromol/L), phenylephrine (DOCA = 0.08, control = 0.53 micromol/L), and serotonin (DOCA = 0.014, control = 0.04 micromol/L, EC20 values). Finally, arteries from DOCA rats contracted with aluminum fluoride had increased sensitivity to G protein antagonists but not to a phospholipase C inhibitor. The enhanced contractile responsiveness in the DOCA arteries may be mediated in part through decreased G(alpha)i levels. However, it is not caused by increased concentrations of G(alpha)q in the cell membrane or by increased phospholipase C sensitivity, and the increased constrictor response to G protein stimulators of phospholipase C appears to depend primarily on increased G protein sensitivity.
Kanagy
N L
NL
Department of Physiology, University of New Mexico School of Medicine, Albuquerque, 87131-5321, USA.
Webb
R C
RC
D017607:Aluminum Compounds / Q000008:administration & dosage; D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism* / Q000503:physiopathology; D003900:Desoxycorticosterone / Q000008:administration & dosage* / Q000037:antagonists & inhibitors; D005459:Fluorides / Q000008:administration & dosage; D019204:GTP-Binding Proteins / Q000378:metabolism*; D006973:Hypertension / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D010455:Peptides; D051381:Rats; D017207:Rats, Sprague-Dawley; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage; D014862:Wasp Venoms / Q000008:administration & dosage
D017607:Aluminum Compounds; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D014662:Vasoconstrictor Agents; D014862:Wasp Venoms; D003900:Desoxycorticosterone; C037500:mastoparan; D019204:GTP-Binding Proteins; D005459:Fluorides; C032311:aluminum fluoride